You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


New data demonstrates long-term benefit of Crysvita for XLH patients

Kyowa Kirin’s Crysvita (burosumab) has new long-term data showing ‘sustained’ benefits for adults living with the rare genetic metabolic bone disease X-linked hypophosphataemia (XLH).